[go: up one dir, main page]

AR092879A1 - Proteinas de fusion de g3p como agentes de union a amiloide - Google Patents

Proteinas de fusion de g3p como agentes de union a amiloide

Info

Publication number
AR092879A1
AR092879A1 ARP130103572A ARP130103572A AR092879A1 AR 092879 A1 AR092879 A1 AR 092879A1 AR P130103572 A ARP130103572 A AR P130103572A AR P130103572 A ARP130103572 A AR P130103572A AR 092879 A1 AR092879 A1 AR 092879A1
Authority
AR
Argentina
Prior art keywords
agents
amiloide
union
fusion proteins
amyloid
Prior art date
Application number
ARP130103572A
Other languages
English (en)
Inventor
Krishnan Rajaraman
Original Assignee
Neurophage Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurophage Pharmaceuticals Inc filed Critical Neurophage Pharmaceuticals Inc
Publication of AR092879A1 publication Critical patent/AR092879A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14111—Inoviridae
    • C12N2795/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14111—Inoviridae
    • C12N2795/14133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Wood Science & Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Agentes y composiciones farmacéuticas para reducir la formación de amiloide y/o para promover la disgregación de proteínas de amiloide. Las composiciones también se pueden usar para detectar amiloide. Proteína de fusión, ácido nucleico, vector, célula huésped.
ARP130103572A 2012-10-02 2013-10-02 Proteinas de fusion de g3p como agentes de union a amiloide AR092879A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261708709P 2012-10-02 2012-10-02
US201261730316P 2012-11-27 2012-11-27
US201361801349P 2013-03-15 2013-03-15
US201361828105P 2013-05-28 2013-05-28

Publications (1)

Publication Number Publication Date
AR092879A1 true AR092879A1 (es) 2015-05-06

Family

ID=49354958

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130103572A AR092879A1 (es) 2012-10-02 2013-10-02 Proteinas de fusion de g3p como agentes de union a amiloide

Country Status (25)

Country Link
US (3) US9688728B2 (es)
EP (1) EP2906235B1 (es)
JP (1) JP6283366B2 (es)
KR (1) KR102101258B1 (es)
CN (1) CN104870008B (es)
AR (1) AR092879A1 (es)
AU (1) AU2013327472B2 (es)
BR (1) BR112015007424A2 (es)
CY (1) CY1120132T1 (es)
DK (1) DK2906235T3 (es)
EA (1) EA033666B1 (es)
ES (1) ES2641373T3 (es)
HR (1) HRP20171413T1 (es)
HU (1) HUE036893T2 (es)
IL (1) IL238021B (es)
LT (1) LT2906235T (es)
MX (1) MX358755B (es)
NZ (1) NZ706838A (es)
PL (1) PL2906235T3 (es)
PT (1) PT2906235T (es)
SI (1) SI2906235T1 (es)
SM (1) SMT201700473T1 (es)
TW (1) TWI613212B (es)
WO (1) WO2014055515A1 (es)
ZA (1) ZA201502940B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201709849TA (en) 2011-11-29 2017-12-28 Proclara Biosciences Inc Use of p3 of bacteriophage as amyloid binding agents
LT2906235T (lt) 2012-10-02 2017-10-25 Proclara Biosciences, Inc. Bakteriofago sulietų baltymų p3, kaip amiloido rišamųjų agentų, naudojimas
US9988444B2 (en) 2013-05-28 2018-06-05 Proclara Biosciences, Inc. Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity
KR20170085132A (ko) 2014-12-03 2017-07-21 프로클라라 바이오사이언시즈, 인크. 글리코실화 신호가 결핍된 변형된 박테리오파지 ｇ3ｐ 아미노산 서열을 포함하는 폴리펩티드
TW202523853A (zh) * 2015-03-27 2025-06-16 美商再生元醫藥公司 偵測生物污染物之組成物及方法
EP3532497B1 (en) 2016-10-26 2024-07-24 The Board of Trustees of the Leland Stanford Junior University Modified immunoglobulin hinge regions to reduce hemagglutination
ES2960493T3 (es) 2018-06-15 2024-03-05 Amyl Therapeutics Motivo de interacción amiloide general (GAIM)
CN115605483A (zh) 2020-07-06 2023-01-13 莫尔根生物有限公司（Kr） 三环双内酯化合物、其生产方法及用途
US20250325558A1 (en) * 2022-05-25 2025-10-23 Alan Jerome Fowler Modulation of bace1 as a therapy for spinocerebellar ataxia
CN115820567B (zh) * 2022-07-26 2025-06-06 成都盛世君联生物技术有限公司 耐高温辅助噬菌体tr-3及其应用
WO2024119183A1 (en) 2022-12-02 2024-06-06 Alzheon, Inc. Methods for treating neurodegenerative disorders with tramiprosate

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
DE68925966T2 (de) 1988-12-22 1996-08-29 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
DE59010908D1 (de) 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
GEP20033082B (en) 1991-03-15 2003-10-27 Amgen Inc Pegylation of Polypeptides
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
CA2131003A1 (en) 1992-05-26 1993-12-09 Raymond G. Goodwin Novel cytokine that binds cd30
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
CA2342967A1 (en) 1998-12-08 2000-06-15 Biovation Limited Modifying protein immunogenicity
US20020052311A1 (en) 1999-09-03 2002-05-02 Beka Solomon Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
US6376117B1 (en) 2000-07-18 2002-04-23 Sofco L.P. Internal fuel staging for improved fuel cell performance
US8022270B2 (en) 2000-07-31 2011-09-20 Biolex Therapeutics, Inc. Expression of biologically active polypeptides in duckweed
RU2363707C2 (ru) 2001-02-19 2009-08-10 Мерк Патент Гмбх Искусственные белки с пониженной иммуногенностью
MXPA03008032A (es) 2001-03-08 2003-12-04 Merck Patent Gmbh Factor de estimulacion de colonias de granulocitos- macrofagos modificado con inmunogenicidad reducida.
AU2002328742A1 (en) * 2001-10-05 2003-04-22 Cangene Corporation Phagemid display system
DE10238846A1 (de) * 2002-08-20 2004-03-04 Nemod Immuntherapie Ag Aktive Fusionsproteine und Verfahren zu ihrer Herstellung
CN101166536B (zh) 2005-02-01 2012-06-27 雷蒙特亚特特拉维夫大学有限公司 治疗与淀粉样蛋白沉积有关的炎症和涉及已活化小胶质细胞的脑部炎症的方法
AU2007214399A1 (en) 2006-02-15 2007-08-23 Ramot At Tel-Aviv University Filamentous bacteriophage displaying protein as a binder of antibodies and immunocomplexes for delivery to the brain
US20090304726A1 (en) 2006-02-15 2009-12-10 Ramot At Tel Aviv University Ltd. Viral display vehicles for treating multiple sclerosis
WO2007109733A2 (en) 2006-03-21 2007-09-27 The Johns Hopkins University Diagnostic and prognostic markers and treatment strategies for multiple sclerosis
WO2007114139A1 (ja) 2006-04-06 2007-10-11 Fumiaki Uchiyama 新規繊維状ファージによるファージディスプレイ
EP2054515B1 (en) 2006-07-21 2012-01-11 Ramot at Tel-Aviv University Ltd. Use of a phage displaying a peptide from an adhesion protein for treating a disease associated with intracellular formation of protein fibrillar inclusions or aggregates
US20100017370A1 (en) 2006-10-11 2010-01-21 Antitope Limited T cell epitope databases
WO2009143470A1 (en) 2008-05-22 2009-11-26 Ramot At Tel Aviv University Ltd. Method for treating disease characterized by plaque
AU2009316326A1 (en) 2008-11-24 2010-05-27 Ramot At Tel-Aviv University Ltd. Method for treating Parkinson' s disease using filamentous bacteriophage
EP2233500A1 (en) * 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
WO2011084714A2 (en) 2009-12-17 2011-07-14 Biogen Idec Ma Inc. STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF
EP2683391B1 (en) 2011-03-11 2015-05-06 Ramot at Tel Aviv University, Ltd. Filamentous bacteriophage for use in the treatment of neurodegenerative tauopathy
SG10201709849TA (en) 2011-11-29 2017-12-28 Proclara Biosciences Inc Use of p3 of bacteriophage as amyloid binding agents
LT2906235T (lt) 2012-10-02 2017-10-25 Proclara Biosciences, Inc. Bakteriofago sulietų baltymų p3, kaip amiloido rišamųjų agentų, naudojimas
US9988444B2 (en) 2013-05-28 2018-06-05 Proclara Biosciences, Inc. Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity
KR20170085132A (ko) 2014-12-03 2017-07-21 프로클라라 바이오사이언시즈, 인크. 글리코실화 신호가 결핍된 변형된 박테리오파지 ｇ3ｐ 아미노산 서열을 포함하는 폴리펩티드

Also Published As

Publication number Publication date
KR102101258B1 (ko) 2020-04-16
AU2013327472A1 (en) 2015-05-21
IL238021B (en) 2019-06-30
BR112015007424A2 (pt) 2021-04-20
EA033666B1 (ru) 2019-11-14
US20170305975A1 (en) 2017-10-26
HRP20171413T1 (hr) 2017-12-15
KR20150063544A (ko) 2015-06-09
US10526377B2 (en) 2020-01-07
EP2906235A1 (en) 2015-08-19
DK2906235T3 (en) 2017-09-25
US9688728B2 (en) 2017-06-27
EP2906235B1 (en) 2017-07-19
LT2906235T (lt) 2017-10-25
SI2906235T1 (sl) 2017-12-29
ES2641373T3 (es) 2017-11-08
US20180354994A1 (en) 2018-12-13
WO2014055515A1 (en) 2014-04-10
CY1120132T1 (el) 2018-12-12
AU2013327472B2 (en) 2017-10-26
MX358755B (es) 2018-09-03
HK1213775A1 (en) 2016-07-15
IL238021A0 (en) 2015-05-31
CN104870008B (zh) 2019-10-01
AU2013327472A2 (en) 2015-06-04
US10208090B2 (en) 2019-02-19
CN104870008A (zh) 2015-08-26
PL2906235T3 (pl) 2017-12-29
JP6283366B2 (ja) 2018-02-21
US20150376239A1 (en) 2015-12-31
TWI613212B (zh) 2018-02-01
HUE036893T2 (hu) 2018-08-28
EA201590690A1 (ru) 2016-04-29
MX2015004119A (es) 2015-10-26
JP2015532290A (ja) 2015-11-09
TW201418279A (zh) 2014-05-16
SMT201700473T1 (it) 2017-11-15
NZ706838A (en) 2017-06-30
PT2906235T (pt) 2017-09-28
ZA201502940B (en) 2017-11-29

Similar Documents

Publication Publication Date Title
AR092879A1 (es) Proteinas de fusion de g3p como agentes de union a amiloide
CL2014002166A1 (es) Proteína de fusión de factor viii recombinante que comprende al polipéptido recombinante extendido xten; composición farmacéutica que la comprende; ácido nucleico que la codifica; vector; célula huésped; método de producción; y uso para tratar una coagulopatía, tal como hemofilia.
DK2831241T3 (da) Kunstige nukleinsyremolekyler til forbedret protein- eller peptidekspression.
UY34663A (es) Acido nucleico y proteina recombinante del gen de la endotoxina axmi345, vectores, células, composiciones y métodos para proteger plantas
UY34885A (es) Proteínas de unión anti-mesotelina
UY34254A (es) Proteínas y péptidos modificados.
EA201500172A1 (ru) Модифицированные полипептиды фактора х и их применение
BR112014024675A8 (pt) célula hospedeira recombinante, cultura celular
BR112015004467A2 (pt) método para controlar a heterogeneidade de proteínas
EA201492221A1 (ru) Полипептиды, имеющие активность трансгалактозилирования
IL235041A0 (en) Recombinant bacterial host cell for protein expression
BR112015022208A8 (pt) proteínas de fusão que compreendem pdgf e partes de ligação de vegf, e métodos de utilização do mesmo
MX356162B (es) Sistema de expresion y secrecion.
AR090903A1 (es) Anticuerpos e inmunoconjugados anti-pmel17
BR112014022788A2 (pt) peptídeo, polipeptídeos, ácido nucleico, composição farmacêutica, conjugado e método in vitro
BR112017013956A2 (pt) proteínas de fusão de citocinas
AR093446A1 (es) Anticuerpos de antihemaglutinina y metodos de uso
BR112015024119A2 (pt) polipeptídeos tendo atividade de fosfolipase a e polinucleotídeos que os codificam
BR112015021753A2 (pt) promotores de levedura provenientes de pichia pastoris
BR112014031039A2 (pt) elementos de dna recombinante para a expressão de proteínas recombinantes em uma célula hospedeira.
UY34662A (es) Acido nucleico y proteina recombinante del gen de la toxina axmi335, vectores, células, composiciones y métodos para proteger plantas
EA201791918A1 (ru) Модификация белков клеток-хозяев
BR112015003724A2 (pt) polipeptídeo isolado, composição, uso de uma composição, polinucleotídeo isolado, constructo de ácido nucleico ou vetor de expressão, célula hospedeira recombinante, e, métodos de produção de um polipeptídeo e de produção de uma proteína.
MX373329B (es) Células eucariotas novedosas y métodos para la expresión recombinante de un producto de interés.
EA201792608A3 (ru) Применение белков p3 бактериофага в качестве агентов, связывающих амилоид

Legal Events

Date Code Title Description
FB Suspension of granting procedure